We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 393

The competition and IP intersect
  • King & Wood Mallesons
  • Australia
  • February 13 2014

In a move which will be closely watched by the pharmaceutical industry, the ACCC has commenced proceedings against Pfizer alleging breaches of the


ACCC opposes Healthscope's proposed acquisition of Brunswick Private Hospital
  • Corrs Chambers Westgarth
  • Australia
  • June 30 2014

On 12 June 2014, the ACCC announced that it will oppose the proposed acquisition of Brunswick Private Hospital by Healthscope Limited (Healthscope


A summary of major developments in key areas - general counsel update - July 2014
  • Herbert Smith Freehills LLP
  • Australia, European Union, Hong Kong, United Kingdom
  • July 15 2014

Legislation, in the form of a Regulation and Directive, has been published in the Official Journal of the European Union which will substantially


Pfizer case shows protecting your own position isn't anti-competitive
  • Clayton Utz
  • Australia
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its


Hospital’s by-laws flatline on the competition table
  • King & Wood Mallesons
  • Australia
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd


Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the


ACCC imposes strict transparency provisions on updated Medicines Australia Code of Conduct
  • King & Wood Mallesons
  • Australia
  • October 28 2014

Roll-out of a new edition of Medicines Australia’s Code of Conduct has struck a roadblock, with the ACCC requesting that Medicines Australia amend


ACCC allegedly misled by Medicines Australia Code of Conduct
  • Russell Kennedy
  • Australia
  • August 25 2014

We previously reported that Medicines Australia submitted its 18th Edition of the Code of Conduct for approval by the ACCC. Subsequently, the Royal


ACCC pursues Pfizer over Lipitor drug
  • HopgoodGanim
  • Australia
  • September 2 2014

Click here to view the video


ACCC proposes to reauthorise collective negotiations by rural doctors
  • Corrs Chambers Westgarth
  • Australia
  • September 11 2013

On 28 August 2013, the ACCC issued a draft determination proposing to allow the Rural Doctors Association of Australia (RDAA) and its state